Johnson & Johnson Report Long-Term Data of Tremfya (guselkumab) in P-III DISCOVER-2 Study for Active Psoriatic Arthritis

 Johnson & Johnson Report Long-Term Data of Tremfya (guselkumab) in P-III DISCOVER-2 Study for Active Psoriatic Arthritis

Johnson & Johnson Report Long-Term Data of Tremfya (guselkumab) in P-III DISCOVER-2 Study for Active Psoriatic Arthritis

Shots:

  • The P-III DISCOVER-2a study involves assessing Tremfya (q4w/ q8w, SC) in bio-naïve patients with active PsA
  • Results: @100wks. complete skin clearance (PASI 100) (59 %/53%); improvement in joint symptoms (ACR 20) (76%/74%). The findings confirmed that the robust efficacy of Tremfya demonstrated in patients @24wks. on physical function, physical aspects of health-related QoL, and resolution of enthesitisb and dactylitisc was also seen through 100wks.
  • Additionally, the extent of radiographic progression was studied through 2yrs. Tremfya is the first and only IL-23 inhibitor therapy approved in the US to treat with active PsA and PsO

Click here ­to­ read full press release/ article | Ref: J&J | Image: Euro Finance

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post